Document Detail

Fatal Mycobacterium colombiense/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report.
Jump to Full Text
MedLine Citation:
PMID:  23336346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Reports of acquired immunodeficiency due to autoantibodies against interferon gamma in the adult population are increasing. The interleukin-12-dependent interferon-gamma axis is a major regulatory pathway of cell-mediated immunity and is critical for protection against a few intracellular organisms, including non-tuberculous mycobacteria and Salmonella spp. We report the first case of a fatal disseminated Mycobacterium colombiense/cytomegalovirus coinfection in an adult woman associated with the acquisition of autoantibodies against interferon-gamma.
CASE PRESENTATION: A 49-year-old woman, born to nonconsanguineous parents in Laos, but who had lived in Canada for the past 30 years, presented with a 1-month history of weight loss, fatigue, cough, and intermittent low-grade fever. A thoracic computed tomography scan revealed an 8 × 7 cm irregular mass impacting the right superior lobar bronchus along with multiple mediastinal and hilar adenopathies. On the fourth day of admission, the patient developed fever with purulent expectorations. Treatment for a post-obstructive bacterial pneumonia was initiated while other investigations were being pursued. Almost every culture performed during the patient's hospitalization was positive for M. colombiense. Given the late presentation of symptoms - at the age of 49 years - and the absence of significant family or personal medical history, we suspected an acquired immunodeficiency due to the presence of anti-interferon-gamma autoantibodies. This was confirmed by their detection at high levels in the plasma and a STAT1 phosphorylation assay on human monocytes. The final diagnosis was immunodeficiency secondary to the production of autoantibodies against interferon-gamma, which resulted in a post-obstructive pneumonia and disseminated infection of M. colombiense. The clinical course was complicated by the presence of a multiresistant Pseudomonas aeruginosa post-endobronchial ultrasound mediastinitis, cytomegalovirus pneumonitis with dissemination, and finally, susceptible P. aeruginosa ventilator-associated pneumonia with septic shock and multiple organ failure, leading to death despite appropriate antibacterial and anti-mycobacterial treatment.
CONCLUSIONS: Although rare, acquired immunodeficiency syndromes should be considered in the differential diagnosis of patients with severe, persistent, or recurrent infections. Specifically, severe non-tuberculous mycobacteria or Salmonella infections in adults without any other known risk factors may warrant examination of autoantibodies against interferon-gamma because of their increasing recognition in the literature.
Authors:
Sébastien Poulin; Claude Corbeil; Mélanie Nguyen; Anik St-Denis; Lise Côté; Françoise Le Deist; Alex Carignan
Related Documents :
12825176 - Association of cd14 promoter gene polymorphism and chlamydia pneumoniae infection.
3223136 - Lectins and their role in a new polyvalent bacterial vaccine against ari.
24201056 - Effects of homologous and heterologous immunization on the reservoir competence of dome...
23943346 - The effects of seasonal forcing on invertebrate-disease interactions with immune priming.
2557346 - Modification of phospholipase c and phospholipase a2 activities during poliovirus infec...
1801346 - Effect of praziquantel on the distribution of interstitial collagen types i and iii and...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2013-01-22
Journal Detail:
Title:  BMC infectious diseases     Volume:  13     ISSN:  1471-2334     ISO Abbreviation:  BMC Infect. Dis.     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-31     Completed Date:  2013-06-18     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  100968551     Medline TA:  BMC Infect Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  24     Citation Subset:  IM    
Affiliation:
Department of Microbiology and Infectious Diseases, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12ème Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada. sebastien.poulin@usherbrooke.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Autoantibodies / immunology*
Coinfection*
Cytomegalovirus Infections / etiology*
Fatal Outcome
Female
Humans
Immunologic Deficiency Syndromes / complications*,  immunology*
Interferon-gamma / immunology*
Middle Aged
Mycobacterium Infections / etiology*
Chemical
Reg. No./Substance:
0/Autoantibodies; 82115-62-6/Interferon-gamma
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Infect Dis
Journal ID (iso-abbrev): BMC Infect. Dis
ISSN: 1471-2334
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2013 Poulin et al.; licensee BioMed Central Ltd.
open-access:
Received Day: 23 Month: 8 Year: 2012
Accepted Day: 11 Month: 1 Year: 2013
collection publication date: Year: 2013
Electronic publication date: Day: 22 Month: 1 Year: 2013
Volume: 13First Page: 24 Last Page: 24
PubMed Id: 23336346
ID: 3561114
Publisher Id: 1471-2334-13-24
DOI: 10.1186/1471-2334-13-24

Fatal Mycobacterium colombiense/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report
Sébastien Poulin1 Email: sebastien.poulin@usherbrooke.ca
Claude Corbeil2 Email: claude.corbeil2@sympatico.ca
Mélanie Nguyen3 Email: melanie.nguyen@gmail.com
Anik St-Denis1 Email: anik.st-denis@recherche-ste-justine.qc.ca
Lise Côté4 Email: lise_cote@inspq.qc.ca
Françoise Le Deist5 Email: francoise.le.deist@umontreal.ca
Alex Carignan1 Email: alex.carignan@usherbrooke.ca
1Department of Microbiology and Infectious Diseases, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12ème Avenue Nord, Sherbrooke, Quebec, J1H 5N4, Canada
2Department of Respirology, Hôpital Charles LeMoyne, Greenfield Park, Longueuil, Quebec, Canada
3Department of Rheumatology and Allergy, Hôpital Charles LeMoyne, Greenfield Park, Longueuil, Quebec, Canada
4Laboratoire de santé publique du Québec (LSPQ), Sainte-Anne-de-Bellevue, Quebec, Canada
5Department of Microbiology and Immunology, Department of Pediatrics and Centre de recherche du CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada

Background

Disseminated non-tuberculous mycobacteria (NTM) infections mainly occur in individuals with impaired cell-mediated immunity, which may result from human immunodeficiency virus (HIV) infection, malignancy (especially hematologic cancers), the use of immunosuppressive drugs, and, more rarely, primary T-cell deficiencies [1]. The interleukin-12 (IL-12)-dependent interferon-gamma (IFN-γ) axis is a major regulatory pathway of cell-mediated immunity and is critical for protection against some intracellular organisms, including NTM and Salmonella spp. [2]. Genetic defects in this axis among the pediatric population, producing Mendelian susceptibility to mycobacterial diseases (MSMD), are well recognized [2,3]. However, since 2004, reports of severe, persistent, or recurrent infections with NTM secondary to acquired autoantibodies to IFN-γ have been increasingly encountered among the adult population [4]. In this study, we report the first case of a fatal disseminated Mycobacterium colombiense/cytomegalovirus coinfection in an adult woman associated with the acquisition of autoantibodies against IFN-γ.


Case presentation

A 49-year-old woman, born to nonconsanguineous parents in Laos, but who had lived in Canada for the past 30 years, presented in May 2010 with a 1-month history of weight loss, fatigue, cough, and intermittent low-grade fever. Her previous family and personal medical history were unremarkable. She could not recall being in contact with tuberculosis. Given that a 7-day course of levofloxacin treatment for presumed right lung pneumonia did not improve her symptoms, she was subjected to further examinations. An initial bronchoscopy showed friable, bleeding, and irregular mucosa of the right upper lobe entry. Biopsies were not feasible, but Ziehl-Neelsen and auramine stains of the bronchoalveolar lavage (BAL) were negative and cytology was normal. A thoracic computed tomography (CT) scan revealed atelectasis caused by an 8 × 7 cm irregular mass impacting the right superior lobar bronchus along with multiple mediastinal and hilar adenopathies (Figure 1a).

Since the most probable diagnosis was a neoplastic process, the patient was discharged home to await a scheduled transthoracic biopsy (TTB). However, when a previous BAL culture was found to be positive for acid-fast bacilli (AFB), she was readmitted to rule out active tuberculosis. Upon presentation, she was afebrile and her vital signs were normal. There was no regional adenopathy, and the physical examination was normal except for reduced vesicular murmur sounds on auscultation over the right lung. The peripheral white blood cell count was 26 × 109/L, with 21 × 109/L neutrophils and 3 × 109/L lymphocytes. The inflammatory syndrome was considered important due to a serum C-reactive protein concentration of 111 mg/L and erythrocyte sedimentation rate of 25 mm/h. The procalcitonin concentration was 19 μg/L. The hemoglobin level was 71 g/L with a mean corpuscular volume of 73 fL, and the platelet count was at 766 × 109/L. Other routine biochemical tests were normal. Polymerase chain reaction (PCR) performed 3 days after admission, using morning sputum, was negative for Mycobacterium tuberculosis complex. On the fourth day, the patient developed fever with purulent expectorations. While other investigations were being pursued, treatment for post-obstructive pneumonia was initiated with piperacillin-tazobactam.

An endobronchial ultrasound (EBUS) revealed purulent secretions and a diminished right superior lobar bronchus caliber. Multiple transbronchial needle aspirations of adenopathies were also performed. Two days later, the patient’s condition necessitated her transfer to the intensive care unit (ICU), and vancomycin was added. The peripheral white blood cell count was 47 × 109/L and a chest X-ray film showed a new infiltration process affecting the right lower lobe and median lobe with an important pleural effusion. Analysis of the pleural fluid showed an uncomplicated exudative effusion (pH >7.2) with a predominance of lymphocytes. On the fourth day in the ICU, endotracheal intubation and support with amines were required for septic shock. The results of mediastinoscopy biopsies followed by a TTB of the mass lesion were non-diagnostic, showing only extensive fibrosis and unspecific acute and chronic reactive lymphoid infiltrates. Granuloma formation was not observed.

On the eight day in the ICU, the first preliminary report of the initial BAL sample revealed that it was positive for M. colombiense, as shown by analyzing genomic deletions and rRNA 16S gene sequencing (Quebec Public Health Laboratory). As radiologic control had also deteriorated (Figure 1b), the decision to commence treatment on the same day with rifampicin, clarithromycin, and ethambutol was taken. Later sensitivity analysis by broth microdilution revealed that M.colombiense was susceptible to clarithromycin with a minimum inhibitory concentration (MIC) of 0.25 mg/L. Rifampin's MIC was 4 mg/L and ethambutol's MIC was >16 mg/L. Although ethambutol and rifampin are useful clinically in cases of Mycobacterium avium complex infections [5], breakpoints for determining susceptibility and resistance have not been established by the Clinical and laboratory standards institute M24-A2 (CLSI M24-A2) [6]. HIV tests were repeatedly negative. Two days later, multiple organ failure (MOF) developed. Since the previous mediastinoscopy culture was positive for a multiresistant Pseudomonas aeruginosa strain (Table 1), vancomycin was stopped and piperacillin-tazobactam was changed to doripenem and tobramycin. On the patient’s 27th day in the ICU, administration of anti-Pseudomonas antibiotics was terminated because her clinical condition was stable. However, when 2 tracheal aspirates were found to be positive for susceptible P. aeruginosa (Table 1) and clinical deterioration was again noted, treatment with piperacillin-tazobactam and ciprofloxacin was started. Unfortunately, the patient died from septic shock with MOF on the 34th day in the ICU.

Interestingly, almost every culture performed during the patient’s hospitalization was positive for M. colombiense (Table 1). Although cytomegalovirus (CMV) serology was not performed for this patient before her death, samples from the final bronchoscopy grew CMV in fibroblast cell culture many days later (Table 1). The pathologist also identified CMV inclusions in the lungs, mediastinal adenopathies, thyroid gland, pancreas, and adrenal glands (Figure 2a). This observation was also confirmed by immunohistochemistry (Figure 2b).

Post-mortem examination of the right lung revealed an organizing pneumonia, and the mediastinum contained a lot of adherence, fibrosis, and adenopathies with lymphoid hyperplasia. No granuloma formation was detected in the lungs or in any of the other organs examined. An immunologic investigation performed before the death of our patient revealed normal counts of lymphocyte populations (CD4+, CD8+, CD19+, CD56+) and normal levels of immunoglobulins. We concluded that a genetic immunological deficit was very unlikely because of the late presentation of symptoms—at the age of 49 years—and the absence of significant family or personal medical history. Instead, we suspected an acquired deficit; thus, we tested for the presence of anti-IFN-γ autoantibodies in the patient’s plasma. The IFN-γ titer—defined as the dilution of a patient’s plasma that inhibits 50% fixation of 125 pg/mL IFN-γ in a standard IFN-γ ELISA assay (eBioscience ELISA kit)—was positive at 1:53725. Therefore, the final diagnosis was immunodeficiency secondary to the production of autoantibodies against IFN-γ, which resulted in post-obstructive pneumonia caused by lymphadenitis and disseminated infection of M. colombiense. The clinical course was complicated by the presence of multiresistant P. aeruginosa infection post-EBUS mediastinitis, CMV pneumonitis with dissemination, and finally, susceptible P. aeruginosa ventilator-associated pneumonia with septic shock and MOF leading to death.


Discussion

A total of 29 cases of disseminated NTM infections secondary to the production of autoantibodies against IFN-γ had been reported [1,2,7,8] before the recent large prospective study by Browne et al. [9]. Compared to control groups, neutralizing anti-IFN-γ autoantibodies was associated with disseminated NTM or other different opportunistic infections among more than 80 patients from Thailand or Taiwan. In these studies, the organs involved included the lymph nodes, bone marrow, bones, lungs, skin, and soft tissues. In contrast to the case reported here, most of them described the formation of complete or poorly formed granulomas. However, several different forms of MSMD are associated with the absence of granuloma formation [10,11], suggesting that our observations may be plausible. Positive blood cultures were infrequently noted [1]. The presence of both rapidly growing NTMs (e.g., M. chelonae, M. fortuitum, and M. abscessus) and slowly growing NTMs (e.g., M. avium complex (MAC), M. szulgai, M. kansasii, M. scrofulaceum, and M. intermedium) has been described, and the most frequently detected are MAC and M. chelonae. Notably, to our knowledge, our case is the first to specifically identify M. colombiense. In fact, M. colombiense is a novel member of the Mycobacterium avium complex (MAC) that was first isolated in 2006 from blood specimens of four HIV-positive patients in Colombia, South America [12]. Interestingly, only 3 reports have shown its capability of causing lymphadenitis, and they were from cervical [13,14] or subclavicular lymph nodes [15]. It was also isolated only twice from respiratory specimen [14]. Previous identifications of MAC organisms often relied on hybridization techniques, which hampered distinguishing between the various MAC species compared to current sequence-based identifications and genotyping [14]. Because no consensus about the preferred anti-mycobacterial regimen exists yet for M. colombiense, we followed current disseminated Mycobacterium avium complex infections guidelines using clarithromycin with rifampin and ethambutol [5].

Pathogens other than NTM or Salmonella spp. have been reported as coinfecting organisms in patients with acquired autoantibodies against IFN-γ. Namely, these include M. tuberculosis, varicella-zoster virus, Burkholderia cocovenenans, Candida, Aspergillus, Achromobacter spp., Enterococcus spp., Streptococcus pyogenes, Penicillium marneffei, Strongyloides stercoralis, Cryptococcus neoformans and Histoplasma capsulatum[1,2,8,9]. However, the direct involvement of these coinfecting organisms in the defect in the IL-12―dependent IFN-γ axis is not entirely clear. Moreover, Pseudomonas spp. have only been described once in coinfection [16]. Since our patient had several other risk factors for P. aeruginosa infection (e.g., ICU, endotracheal intubation, and antibiotics) and because Pseudomonas is not an intracellular pathogen, it seems unlikely to be a direct consequence of a defect in the IL-12―dependent IFN-γ axis. Post-mortem serum sample was collected to measure CMV-specific immunoglobulin G (CMV-IgG) and CMV-specific immunoglobulin M (CMV-IgM) markers. As our patient was IgM negative, and IgG positive, we assumed that the CMV infection was most likely a reactivation process. Prior to our report, CMV coinfection had only been described in 1 case [4] of acquired autoantibodies against IFN-γ. However, cases of CMV infection have been described in MSMD [3,17]. Therefore, it is possible that the IL-12―dependent IFN-γ axis, strongly diminished by autoantibodies in our patient, played a significant role in her disseminated CMV infection.

Similar to the patient described in the present study, cases of acquired autoantibodies against IFN-γ have mainly been reported in Asian female patients [1]. Nonetheless, this is the first reported case from Laos. The high incidence rate in Asian populations may be associated with an unknown HLA allele variant [2]. In contrast to what is sometimes observed, our patient did not present any known autoimmune endocrinopathy or reactive skin diseases such as Sweet’s syndrome or pustular psoriasis [1,2]. Given the severe presentation of our case and the high titer of autoantibodies detected, we hypothesize that such autoantibodies would produce a strong inhibitory effect against IFN-γ signal transduction and IFN-γ―dependent upregulation of TNF-α and IL-12, as was previously shown by Patel et al.[16]. Naturally occurring anti-IFN-γ autoantibodies have been previously described in cases of viruses and mycobacteria infections. However, they usually occurred at low titers and were biologically inactive [16,18]. To confirm our hypothesis, we performed a STAT1 (implicated in the IFN-γ―dependent upregulation of TNF-α and IL-12 [19]) phosphorylation assay using FACSCanto flow cytometry (BD Biosciences) on preserved plasma sample (Figure 3). As expected, phosphorylation of STAT1 in human monocytes after stimulation with INF-γ was inhibited by the patient's plasma, but not when the monocytes were stimulated with IFN-α. We also tested HIV serology twice, and found the immunologic screening to be normal. Since the patient was not known to have any other risk factor for depressed cell-mediated immunity, it is likely that our diagnosis is accurate.

Outcomes in cases of acquired autoantibodies to IFN-γ with NTM infections in the adult population range from fatal infection to complete recovery. These cases frequently result in refractory infection with recurrent or relapsing episodes, despite aggressive and prolonged treatment with 3 or more anti-mycobacterial agents. Additional adjunctive therapies—such as plasmapheresis, intravenous immunoglobulins, exogenous IFN-γ, and cyclophosphamide followed by corticotherapy—have been reported with varying rates of success. In a recent study by Browne et al.[7], 4 cases of refractory disease treated with rituximab showed clinical, radiological, and laboratory evidence of therapeutic improvement, including improved IFN-γ signaling and reduction in anti-IFN-γ autoantibody levels. The rare fatal cases [4,8,20] described by Browne and colleagues were infections that did not respond to months of anti-mycobacterial therapy. Therefore, we believe that our patient is the first to present a fulminant evolution, which led to death in her first hospitalization. This may be explained by the stepwise addition of severe Pseudomonas and disseminated CMV coinfections in a patient already weakened by NTM infection. Despite early initiation (on the same day as the preliminary mycobacterial culture result was known) of anti-mycobacterial treatment based on current recommendations for Mycobacterium avium complex disseminated infections, it is likely that the other coinfections had progressed significantly enough to cause mortality.

Staining of blood samples for STAT1 phosphorylation

One hundred microliter (μl) of normal heparinized whole blood were incubated or not either with 20μl of IFN-γ (10000 IU/ml) or IFN-α (10000 IU/ml) premixed with patient plasma or control plasma (V/V:1/1) for 15 minutes at 37°C. Erythrocytes were lysed with BD phosflow™ Lyse/Fix Buffer (1X) for 10 minutes at 37°C., After surface staining with FITC-conjugated anti-CD14 antibody, cells were permeabilized with BD phosflow™ Perm Buffer III, followed by intracellular staining with Alexa 647-conjugated antibody recognizing pSTAT1 (Y701). Data acquisition was performed by FACSCanto flow cytometry (BD Biosciences) and analysed with FCS Express 4 Flow Research Edition. Fluorescence histogram displays STAT1 phosphorylation gated on CD14+ population (Figure 3).


Conclusions

This case demonstrates that, although rare, primary or acquired immunodeficiency syndromes should be considered in the differential diagnosis of patients with severe, persistent, or recurrent infections. Specifically, severe NTM or Salmonella infections in adults without any other known risk factors may warrant examination of autoantibodies against IFN-γ. Early recognition is vital in such cases in order to consider suitable treatment options, including, for example, the use of rituximab [7,19].

Consent

Written informed consent was obtained from the next of kin of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal.


Abbreviations

NTM: Non-tuberculous mycobacteria; INF-γ: Interferon-gamma; MSMD: Mendelian susceptibility to mycobacterial diseases; BAL: Bronchoalveolar lavage; TTB: Transthoracic biopsy; AFB: Acid-fast bacilli; EBUS: Endobronchial ultrasound; MOF: Multiple organ failure; MIC: Minimum inhibitory concentration.


Competing interests

The authors declare that they have no competing interests.


Authors’ contributions

SP drafted and wrote the manuscript. CC and MN took care of the patient and contributed to coordinating the manuscript. ASD carried out the immunoassays. LC carried out the microbiological assays. FLD carried out the immunoassays and contributed to coordinating the manuscript. AC contributed to the draft of the manuscript and revised the manuscript. All authors have read the manuscript and approved its final version.


Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/13/24/prepub


Acknowledgements

We would like to thank Dr. Philippe Martin, Dr. Marc-André Smith and Dr. Véronique Lapointe for their support.


References
Kampitak T,Suwanpimolkul G,Browne S,Suankratay C,Anti-interferon-gamma autoantibody and opportunistic infections: case series and review of the literatureInfectionYear: 201139657110.1007/s15010-010-0067-321128092
Picque JB,Blot M,Binois R,Jeudy G,Simonet AL,Cagnon J,Mahy S,Duong M,Buisson M,Chavanet P,Piroth L,[Recurrent non tuberculous mycobacterial infections: think about anti-interferon-gamma autoantibodies!]Rev Med InterneYear: 20123310310610.1016/j.revmed.2011.11.01222236500
van de Vosse E,van Dissel JT,Ottenhoff TH,Genetic deficiencies of innate immune signalling in human infectious diseaseLancet Infect DisYear: 2009968869810.1016/S1473-3099(09)70255-519850227
Doffinger R,Helbert MR,Barcenas-Morales G,Yang K,Dupuis S,Ceron-Gutierrez L,Espitia-Pinzon C,Barnes N,Bothamley G,Casanova JL,Longhurst HJ,Kumararatne DS,Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunityClin Infect DisYear: 200438e10e1410.1086/38045314679469
Griffith DE,Aksamit T,Brown-Elliott BA,Catanzaro A,Daley C,Gordin F,Holland SM,Horsburgh R,Huitt G,Iademarco MF,Iseman M,Olivier K,Ruoss S,von Reyn CF,Wallace RJ Jr,Winthrop K,Subcommittee ATSMD, American Thoracic S,Infectious Disease Society of A: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseasesAm J Respir Crit Care MedYear: 200717536741610.1164/rccm.200604-571ST17277290
Clinical and Laboratory Standards Institute (CLSI)Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard— SecondYear: 2012M24-A2Clinical and Laboratory Standards Institute, Wayne, PA, USA
Browne SK,Zaman R,Sampaio EP,Jutivorakool K,Rosen LB,Ding L,Pancholi MJ,Yang LM,Priel DL,Uzel G,Freeman AF,Hayes CE,Baxter R,Cohen SH,Holland SM,Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infectionBloodYear: 20121193933393910.1182/blood-2011-12-39570722403254
Tang BS,Chan JF,Chen M,Tsang OT,Mok MY,Lai RW,Lee R,Que TL,Tse H,Li IW,To KK,Cheng VC,Chan EY,Zheng B,Yuen KY,Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferonClin Vaccine ImmunolYear: 2010171132113810.1128/CVI.00053-1020445006
Browne SK,Burbelo PD,Chetchotisakd P,Suputtamongkol Y,Kiertiburanakul S,Shaw PA,Kirk JL,Jutivorakool K,Zaman R,Ding L,Hsu AP,Patel SY,Olivier KN,Lulitanond V,Mootsikapun P,Anunnatsiri S,Angkasekwinai N,Sathapatayavongs B,Hsueh PR,Shieh CC,Brown MR,Thongnoppakhun W,Claypool R,Sampaio EP,Thepthai C,Waywa D,Dacombe C,Reizes Y,Zelazny AM,Saleeb P,Rosen LB,Mo A,Iadarola M,Holland SM,Adult-onset immunodeficiency in Thailand and TaiwanN Engl J MedYear: 201236772573410.1056/NEJMoa111116022913682
Doffinger R,Patel S,Kumararatne DS,Human immunodeficiencies that predispose to intracellular bacterial infectionsCurr Opin RheumatolYear: 20051744044610.1097/01.bor.0000166387.70475.dd15956841
Sexton P,Harrison AC,Susceptibility to nontuberculous mycobacterial lung diseaseEur Respir JYear: 2008311322133310.1183/09031936.0014000718515557
Murcia MI,Tortoli E,Menendez MC,Palenque E,Garcia MJ,Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variantInt J Syst Evol MicrobiolYear: 2006562049205410.1099/ijs.0.64190-016957098
Esparcia O,Navarro F,Quer M,Coll P,Lymphadenopathy caused by Mycobacterium colombienseJ Clin MicrobiolYear: 2008461885188710.1128/JCM.01441-0718305134
Despierres L,Cohen-Bacrie S,Richet H,Drancourt M,Diversity of Mycobacterium avium subsp. hominissuis mycobacteria causing lymphadenitis, FranceEur J Clin Microbiol Infect DisYear: 2012311373137910.1007/s10096-011-1452-222042560
Vuorenmaa K,Ben Salah I,Barlogis V,Chambost H,Drancourt M,Mycobacterium colombiense and pseudotuberculous lymphadenopathyEmerg Infect DisYear: 20091561962010.3201/eid1504.08143619331753
Patel SY,Ding L,Brown MR,Lantz L,Gay T,Cohen S,Martyak LA,Kubak B,Holland SM,Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infectionsJ ImmunolYear: 20051754769477616177125
Patel SY,Doffinger R,Barcenas-Morales G,Kumararatne DS,Genetically determined susceptibility to mycobacterial infectionJ Clin PatholYear: 2008611006101210.1136/jcp.2007.05120118326015
Revoltella RP,Natural and therapeutically-induced antibodies to cytokinesBiotherapyYear: 19981032133110.1007/BF026785529592020
Browne SK,Holland SM,Immunodeficiency secondary to anticytokine autoantibodiesCurr Opin Allergy Clin ImmunolYear: 20101053454110.1097/ACI.0b013e3283402b4120966748
Hoflich C,Sabat R,Rosseau S,Temmesfeld B,Slevogt H,Docke WD,Grutz G,Meisel C,Halle E,Gobel UB,Volk HD,Suttorp N,Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenansBloodYear: 200410367367510.1182/blood-2003-04-106512947000

Figures

[Figure ID: F1]
Figure 1 

a Thoracic CT scan at presentation. Irregular mass impacting the right superior lobar bronchus. b Thoracic CT scan on the eighth day in the ICU. Extensive right pulmonary consolidation.



[Figure ID: F2]
Figure 2 

a CMV inclusion. Histological analysis of the lung reveals a very large cell that displays a large violet intranuclear inclusion with a small clear halo (typical owl-eye inclusion; arrow). b CMV immunohistochemistry. Immunohistochemical analysis of the lung reveals anti-CMV positive cells (arrows).



[Figure ID: F3]
Figure 3 

Inhibition of INF-γ-induced STAT1 phosphorylation in control monocytes by patient’s plasma. Fluorescence histogram displays STAT1 phosphorylation gated on CD14+ (monocytes) population. Whole blood samples were incubated without (−−--) or with INF-γ (1000 IU/ml)(left panel), or with INF-α (1000 IU/ml) (Right panel) pre-mixed with patient plasma (—) or control plasma (—).



Tables
[TableWrap ID: T1] Table 1 

Culture specimens during the patient’s hospitalization


Specimen Date Auramine NTM Other
BAL
7/6/10
-
M. colombiense
-
Sputum
27/6/10
-
M. colombiense
-
Sputum
28/6/10
1–9/100
M. colombiense
-
EBUS
30/6/10
-
M. colombiense
-
Sputum
2/7/10
-
-
C. albicans
Mediastinoscopy
6/7/10
-
M. colombiense
P. aeruginosa
Tracheal aspirate
8/7/10
1–9/100
M. colombiense
-
Tracheal aspirate
9/7/10
1–9/100
M. colombiense
-
Tracheal aspirate
10/7/10
1–9/100
M. colombiense
-
Right pleural effusion
11/7/10
-
M. colombiense
-
Bronchial lavage
18/7/10
1–2/100
M. colombiense
-
Bronchial lavage
26/7/10
-
M. colombiense
-
Bronchial lavage
29/7/10
-
-
CMV
Tracheal aspirate
31/7/10
-
-
P. aeruginosa
Tracheal aspirate 2/8/10 - M. colombiense P. aeruginosa


Article Categories:
  • Case Report

Keywords: Atypical mycobacteria, Acquired immunodeficiency, Autoantibody, Interferon-gamma, Cytomegalovirus, Mycobacterium colombiense.

Previous Document:  Investigation of STW 5 (Iberogast®) preventive effects in experimental sepsis.
Next Document:  The impact of Clostridium difficile colitis following closure of a diverting loop ileostomy: results...